TransCure bioServices

The only CRO specialized in full human immune system mouse disease models for Cancer, Infectious, Inflammation and Vaccines.
TransCure bioServices SAS was incorporated in 2012 in Archamps, France, near Geneva, Switzerland as a spin-off from TransCure Biosciences, the Universities of Geneva, Pretoria, and Zürich.

Our goal is to offer predictive in vivo pharmacology tools for studying diseases of the human immune system, liver, pancreas and skin. We offer access to human immune system mouse models for preclinical drug development that target diseases such as HIV, CMV, Hepatitis C, Malaria, Dengue, autoimmune (e.g. SLE), inflammatory (e.g. colitis, RA), cancers, PDX, and orphan/rare indications.

Your Advantages:

• Save Time and Budget
• Focus on the most promising clinical candidate
• HuData for IND filling
• One-stop-shop for in vivo pharmacology
• De-risking Translational Projects
• Flexibility and Adaptability
• Competitive FTE Rate
• Access to BSL-2 and 3 lab. and animal facilities
• Tailored-made protocols and study designs

Our Assets:

• 600 fully detailed PDX's for I-O, cancer studies

• Biosafety level-2 and -3 accredited animal & lab facilities
• State of the Art Flow Cytometry Platform
• Cell culture and Molecular Biology facilties
• Optimized tailor-made protocol designs
• Swiss quality and Pharma experienced team
• Recognized expertise in flow cytometry analysis
• Innovation programs: EU grants: Eurostars, Interreg & Horizon 2020
• Client Tax Reduction (CIR)

Efficacy Study of a ​drug candidate to reduce SLE pathophysiology in SLE PBMC mouse models.

Evaluation of Test compound on GVHD symptoms induced by human PBMC in mouse models.
• human PBMC injection (multiple donors)
• Treatment : controls, Test compound
• Blood sampling
• GVHD clinical scoring
• Peripheral blood analysis by flow cytometry

PDX for hu-mouse models: more than 600 PDX's fully detailed are available

Immuno-oncology (IO) studies and drug development require good predictive models for clinical study designs. Using full human immune system reconstitution in mouse models and PDX from patients is an essential tool to select/proifile the best pre-clinical candidates. We offer a catalog of fully characterised PDX (patient history, mutations, genomic data) larger than 600 tumors. We provide this service worldwide, just need to send us your drug candidate, and which PDX to use with or without the presence of human immune system. Highly competitive pricing.

Human immune system full reconstitution in mouse models for PDX, cancer, HIV, IBD, vaccines

TransCure bioServices is a CRO who has developed unique Research & Development (R&D) platforms, called the Humanized Immune System (HIS) mouse model.

Toward a more predictive preclinical tumor, PDX, HIV, inflammation mouse models

Conventional Immunodeficient mouse models only monitor the effect of a drug on the tumor itself. With the huamn immune system mouse models of tumor growth you now can evaluate the direct interactions between the Human Immune System and the tumor. We have >600 PDX full characterized for hu-PDX studies.

Solid (breast, ovarian,...) and Liquid (T-cell lymphoma, B-cell Lymphoma, AML) can develop in Humanized mice

Applications:

• Depleting Antibody with ADCC/CDC activity
• Bi-specific Antibody targeting effector cells to the cancer antigen
• Drug targeting human leukocyte antigen and human specific pathway on lymphocytes

This huMouse models have been adapted in 3 main therapeutic areas :

• Oncology-Immunology and PDX
• Human Immunodeficiency Virus (HIV)
• Inflammatory Bowel Diseases

Others platform are also available in inflammatory, auto-immune and infectious diseases. Contact us for more information.

We provide access to these platforms as a fee-for-service for the pharmaceutical companies, biotechs as well as academic laboratories which profile new drugs (NCE, peptide, mAb, vaccines) targeting immuno-related diseases and novel anti-HIV/AIDS therapies.

We have many years of experience with the HIV mouse model. We offer access to HIV mice for anti-HIV drug companies that are interested by preclinical drug profiling in relation to efficacy, latency, resistance and/or rebound parameters.

Compared to SIV monkey models, HIV mice are cheaper, safer, and ethically acceptable. Current tri-therapy are showing similar efficacy on HIV mice than on HIV patients.

HIV Mouse Model ADVANTAGES:

• Clear translational efficacy serving unmet medical needs for anti-HIV drugs testing in HIV mice
• Primate models are costly, lengthy, and ethically challenging
• Mimics nicely human full blown disseminated HIV infection
• Sensitive to HAART
• Models of HIV rebound, latency and resistance available

TransCure bioServices unique Research & Development platforms will help you developing new therapies targeting Inflammation and Autoimmune diseases, such as:

• Inflammatory Bowel Disease (IBD)
• Rheumatoid Arthritis (RA)
• Systemic Lupus Erythematosus (SLE)
• Chronic Obstructive Pulmonary Disease (COPD)
• Asthma
• Skin diseases
• Multiple Sclerosis (MS)

With our enhanced Human Immune System mouse model (eHIS), the myeloid lineage differentiation and the production of antigen-presenting cells is considerably improved.

Our innovative mouse model allows the development of:

• a full immune response, e.g Isotype switching, IgG production
• cellular cytotoxic response

The eHIS mouse models technology can be applied to multiple indications and pathologies such as vaccine response, antibody production, infectious diseases and autoimmune diseases.

Immunophenotyping, leukocyte population by FACS

The Humanized liver mouse model (Huliver mouse) is a smarter predictive preclinical drug development that ensure higher chances of clinical success in further clinical phases.

HuLiver mouse models developed by TransCure bioServices can be applied to :

• liver-related pathologies such as HBV/HCV, NAFLD, hepatocarcinoma or parasitic such as plasmodium
• liver metabolism indications
• Current tox/ADME studies for small and large molecules or vaccines
• Combo HuLiver/HIS